4.14
price up icon0.98%   0.04
after-market After Hours: 4.11 -0.03 -0.72%
loading
Alumis Inc stock is traded at $4.14, with a volume of 503.86K. It is up +0.98% in the last 24 hours and up +38.00% over the past month. Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
See More
Previous Close:
$4.10
Open:
$4.1
24h Volume:
503.86K
Relative Volume:
0.59
Market Cap:
$397.46M
Revenue:
-
Net Income/Loss:
$-238.77M
P/E Ratio:
-0.1544
EPS:
-26.808
Net Cash Flow:
$-216.62M
1W Performance:
+7.25%
1M Performance:
+38.00%
6M Performance:
-44.65%
1Y Performance:
-66.34%
1-Day Range:
Value
$4.035
$4.27
1-Week Range:
Value
$3.75
$4.28
52-Week Range:
Value
$2.7601
$13.11

Alumis Inc Stock (ALMS) Company Profile

Name
Name
Alumis Inc
Name
Phone
650-231-6625
Name
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
Employee
184
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
ALMS's Discussions on Twitter

Compare ALMS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALMS
Alumis Inc
4.14 423.08M 0 -238.77M -216.62M -26.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
456.87 120.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.46 59.88B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
392.24 44.31B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
670.33 36.65B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
301.13 32.46B 3.81B -644.79M -669.77M -6.24

Alumis Inc Stock (ALMS) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-25-25 Initiated Wells Fargo Overweight
Jun-10-25 Resumed Guggenheim Buy
Jan-30-25 Initiated Oppenheimer Outperform
Oct-31-24 Initiated Robert W. Baird Outperform
Oct-17-24 Initiated H.C. Wainwright Buy
Jul-23-24 Initiated Cantor Fitzgerald Overweight
Jul-23-24 Initiated Guggenheim Buy
Jul-23-24 Initiated Leerink Partners Outperform
Jul-23-24 Initiated Morgan Stanley Overweight
View All

Alumis Inc Stock (ALMS) Latest News

pulisher
Jul 31, 2025

What institutional investors are buying Alumis Inc. stockTop Growth Planner For Every Investor - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 30, 2025

When is Alumis Inc. stock expected to show significant growthStock Strategy Trend Scanner To Watch Now - jammulinksnews.com

Jul 30, 2025
pulisher
Jul 30, 2025

Is Alumis Inc. a growth stock or a value stockStock Strategy Tracker For Every Investor - jammulinksnews.com

Jul 30, 2025
pulisher
Jul 30, 2025

What makes Alumis Inc. stock price move sharplyAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it

Jul 30, 2025
pulisher
Jul 29, 2025

Alumis (ALMS) Merges with ACELYRIN - Insider Monkey

Jul 29, 2025
pulisher
Jul 28, 2025

Alumis Inc.: Promising Pipeline and Strategic Advancements Justify Buy Rating - TipRanks

Jul 28, 2025
pulisher
Jul 28, 2025

How strong is Alumis Inc. company’s balance sheetTop Growth Entry Points With Low Risk - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What markets is Alumis Inc. expanding into Is ELPW stock a good long term investment optionMaximize returns with smart investment plans - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What is the dividend policy of Alumis Inc. stockUnlock your trading potential today - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does Alumis Inc. generate profit in a changing economyInvest confidently with professional advice - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What are analysts’ price targets for Alumis Inc. in the next 12 monthsHigh-performance investment picks - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

What is the risk reward ratio of investing in Alumis Inc. stockAccelerated capital growth - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

Is Alumis Inc. stock a good hedge against inflationBest Stocks for Capital Safety - metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

What analysts say about Alumis Inc. stockAccelerated capital growth - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Alumis Inc. Stock Analysis and ForecastFree Investment Community - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Alumis Inc.: Buy Rating Affirmed Amid Promising ESK-001 Developments and Strong Financial Projections - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

Alumis initiated with an Overweight at Wells Fargo - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

What institutions are buying Alumis Inc. stock nowExplosive wealth accumulation - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

Is Alumis Inc. a good long term investmentSuperior capital gains - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

What drives Alumis Inc. stock priceUnbelievable profit margins - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Alumis completes enrollment in lupus treatment phase 2b trial By Investing.com - Investing.com India

Jul 24, 2025
pulisher
Jul 24, 2025

Alumis completes enrollment in lupus treatment phase 2b trial - Investing.com

Jul 24, 2025
pulisher
Jul 24, 2025

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus - The Manila Times

Jul 24, 2025
pulisher
Jul 24, 2025

Alumis Inc. Completes Patient Enrollment in LUMUS Phase 2b Trial of ESK-001 for Systemic Lupus Erythematosus, Topline Data Expected Q3 2026 - Nasdaq

Jul 24, 2025
pulisher
Jul 24, 2025

Major Breakthrough: 408 Patients Enrolled in Advanced Trial for New Oral Lupus Treatment - Stock Titan

Jul 24, 2025

Alumis Inc Stock (ALMS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$74.89
price down icon 3.43%
$36.80
price down icon 0.86%
$107.28
price up icon 2.00%
$26.37
price down icon 1.09%
$107.50
price down icon 2.32%
biotechnology ONC
$301.13
price up icon 0.40%
Cap:     |  Volume (24h):